Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

24 June 2022

READ MOREBiolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

12 May 2022

READ MOREAkston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster

12 April 2022

READ MOREAkston Biosciences CEO to Present at the World Vaccine Congress

7 April 2022

READ MOREAkston Biosciences Doses First Volunteers in Phase II/III Clinical Trial of Low Cost, Shelf Stable COVID-19 Vaccine

31 March 2022

READ MOREAkston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster

17 March 2022

READ MOREAkston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries

8 February 2022

READ MOREAkston Biosciences Announces Publication in Vaccine of Positive Data for a Room Temperature Protein Subunit COVID-19 Vaccine

21 December 2021

READ MOREAkston Biosciences Announces Positive Top-Line Data from Phase II Study of COVID-19 Vaccine in the Netherlands 

19 November 2021

READ MOREAkston Biosciences Doses First Subjects in Phase II Clinical Trial in India of Second-Generation COVID-19 Vaccine

5 August 2021

READ MOREAkston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine